Janssen Announces European Commission Decision for Expanded Use of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL)
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Comm
PIQRAY® is approved and now available in Canada as the first and only treatment specifically for patients with a PIK3CA mutation in HR-positive, HER2-negative advanced breast cancer
Approval is based on results from SOLAR-1, where PIQRAY®in combination with fulvestrant nearly doubl
Gastrointestinal stromal tumor (GIST) targeted new drugs! Avapritinib will be approved in the EU in September
Blueprint Medicines announced that the European Medicines Agency (EMA) Committee for Medicinal Produ
Gilead's Veklury has been approved：Veklury is the First Approved Treatment Option for COVID-19 in the European Union
At present,The COVID-19 epidemic continues to spread rapidly around the world. As of 01am, July 04,
Dear Customers,Unfortunately, we have to cancel the plan for our participation in the CPHI North Ame
New medicine for insomnia! Eisai double-acting orexin receptor antagonist Dayvigo (lemborexant) is launched in the US!
Japanese pharmaceutical company Eisai recently announced the launch of Dayvigo (lemborexant), a new
On May 6, the FDA approved the listing of Novartis Tabrecta (capmatinib) for the treatment of patien
The cortisol synthesis inhibitor Isturia developed by Recordati has been approved by the European Union!
On January 16, 2020, the Italian pharmaceutical company Recordati recently announced that the Europe
On March 17th, the State Council's joint prevention and control mechanism held a press conferenc